News - Empowering Personalized Medicine

June 30, 2023 – Genomenon Accelerates Quest to Curate Entire Human Genome With Boston Genetics Acquisition

GenomeWeb | In acquiring longtime partner Boston Genomics this week, Genomenon is stepping up its efforts to become the first entity to curate the entire human genome, though it may be the only one to have declared such an intention. By adding Cambridge, Massachusetts-based Boston Genetics’ team of about 75 genetic scientists — and doubling its total headcount — Genomenon now claims to have an inside track toward its goal, which CEO Mike Klein said is intended to combine artificial intelligence and next-generation sequencing to accelerate diagnosis of rare diseases and inform drug discovery. Continue Reading….

June 29, 2023 – Genomenon in Ann Arbor Acquires Boston Genetics to Speed Curation of Human Genome

Technology Networks | Genomenon Inc. has announced it has acquired Boston Genetics, a genomics interpretation and curation company. By combining Genomenon’s AI-powered platform for genomic knowledge and tech-enabled scientific expertise with Boston Genetics’ substantial team of genetic scientists, Genomenon is now in position to be the first company to curate the entire human genome. The insights through this curation, starting with the clinical exome, will be invaluable in Genomenon’s mission to save and improve lives by making genomic information actionable. Continue Reading….

June 27, 2023 – Genomenon Acquires Boston Genetics to Accelerate Curation of Human Genome

IT News Online | Genomenon Inc., a leader in Genomic Intelligence, today announced it has acquired Boston Genetics, a genomics interpretation and curation company. By combining Genomenon’s unrivaled AI-powered platform for genomic knowledge and tech-enabled scientific expertise with Boston Genetics’ substantial team of genetic scientists, Genomenon is now in the lead position to be the first company to curate the entire human genome. Continue Reading….

June 27, 2023 – Genomenon acquires Boston Genetics to accelerate curation of human genome

R&D World | Genomenon Inc., a Genomic Intelligence company, announces it has acquired Boston Genetics, a genomics interpretation and curation company. By combining Genomenon’s unrivaled AI-powered platform for genomic knowledge and tech-enabled scientific expertise with Boston Genetics’ substantial team of genetic scientists, Genomenon is now in the lead position to be the first company to curate the entire human genome. Continue Reading….

January 5, 2023 – Trendspotting: What’s Coming for Bio-IT in 2023

Bio-IT World | We spoke with several Bio-IT World community leaders, including Genomenon CSO, Dr. Mark Kiel, to gain insights about their predictions for the coming year. For the first time in two years, COVID was not the primary topic of conversation. Instead, using artificial intelligence (AI) and large language models (LLMs) to accelerate workflows and develop novel therapies are expected to be the primary focal points this year. Continue Reading….

December 5, 2022 – Partnership hopes to advance precision drug development

Drug Discovery World | A new partnership between industry and three rare disease foundations has formed with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders. AI-driven genomics company Genomenon will partner with COMBINEDBrain, SynGAP Research Fund, and SLC-6A1 Connect and their pharma partners to deliver genomic data on their diseases of focus. Continue Reading….

November 29, 2022 – Genomenon Partners With Neurodevelopmental Disease Groups on Drug Development

GenomeWeb | Genomenon said Tuesday that it is partnering with three disease research foundations in hopes of accelerating development of new “precision” drugs to treat rare neurodevelopmental diseases. The three organizations are COMBINEDBrain, the SynGAP Research Fund, and SLC-6A1 Connect, not- for-profit organizations in search of effective treatments for diseases that currently have none. Continue Reading….

November 29, 2022 – Genomenon collaborates with rare disease foundations on drug development

Drug Discovery and Development | The AI-driven genomics company Genomenon has announced that it will work with COMBINEDBrain, SynGAP Research Fund and SLC-6A1 Connect. COMBINEDBrain is a 501(c)(3) company focused on developing new treatments for neurodevelopmental disorders. COMBINEDBrain partners with more than 30 neurodevelopmental rare disease foundations, including SynGAP Research Fund and SLC6A1 Connect. “Our collaboration with Genomenon represents a big step toward finding a cure for genetic developmental disorders,” said COMBINEDBrain founder Dr. Terry Jo Bichell in a news release. “We are excited for what the future holds.” Continue Reading….

November 3, 2022 – New Study Presents Novel Solution to Increasing Diagnostic Yield and Accelerating Diagnosis of Rare Disease

Healthcare Tech Outlook | Genomenon, Inc, an AI-driven genomics company, announced the publication of a paper in Human Mutation summarizing current knowledge of clinical and genetic findings in patients with ENPP1 deficiency. The study, completed in collaboration with Inozyme Pharma is the largest ever gathered, and demonstrates the necessity of comprehensive genomic data for accelerating the diagnosis of rare disease. Continue Reading….

October 31, 2022 – Novel Solution Increases Diagnostic Yield, Accelerates Rare Disease Diagnoses, Study Show

clpmag | Genomenon, an AI-driven genomics company, announced the publication of a paper in Human Mutation summarizing current knowledge of clinical and genetic findings in patients with ENPP1 Deficiency. The study, completed in collaboration with Inozyme Pharma, demonstrates the necessity of comprehensive genomic data for accelerating the diagnosis of rare disease, the company says. Continue Reading….

September 7, 2022 – Genomenon Mastermind with ClinVar

GenomeWeb | Genomenon said this week that it has integrated all the variants and pathogenicity interpretations from the US National Institutes of Health’s ClinVar database into its artificial intelligence-based Mastermind Genomic Search Engine. With the integration, Mastermind users will no longer have to go outside the Genomenon platform to find information within ClinVar, and the search will incorporate ClinVar data alongside other results. Continue Reading….

August 24, 2022 – BeginNGS Program Seeks to Improve Pediatric Rare Disease Dx, Treatment via Rapid NGS, Data Curation

American Association for the Advancement of Science (AAAS) | Rady Children’s Institute for Genomic Medicine (RCIGM^®) today announced the publication of a peer-reviewed study in the American Journal of Human Genetics (AJHG) describing a scalable prototype for newborn screening (NBS) that includes the diagnosis of genetic diseases by rapid Whole Genome Sequencing (rWGS^®) and virtual acute management guidance. Continue Reading….

August 2, 2022 – Genomenon to Curate Genes for Rady Children’s BeginNGS Newborn Screening Panel

GenomeWeb | Genomenon said Tuesday that it has been named the exclusive gene curation partner for Rady Children’s Institute for Genomic Medicine’s (RCIGM^®) recently launched BeginNGS newborn screening panel. Ann Arbor, Michigan-based Genomenon said that it will curate all genes in the panel and deliver “comprehensive” data about variants within those genes to clinicians, with the goal of improving outcomes in infants with rare genetic diseases. Continue Reading….

July 26, 2022 – Automated Genome-to-Treatment System Could Help Manage Genetic Disease

Inside Precision Medicine | The results of a research project led by Rady Children’s Institute for Genomic Medicine (RCIGM) show that an automated, virtual disease management system that includes fast whole genome sequencing and analysis could help to manage genetic diseases better. The new GTRx prototype brings together different research streams and was completed with the help of industry partners Alexion, AstraZeneca, Fabric Genomics, Genomenon, Illumina, and SL Data Strategies, as well as Keck Graduate Institute, Rady Children’s Hospital–San Diego, and UC San Diego departments of Pediatrics and Neuroscience. Continue Reading….

July 26, 2022 – Study supports potential of genome-to-treatment to guide physicians in the management of 500 genetic diseases

Medical Xpress | Rady Children’s Institute for Genomic Medicine (RCIGM) today announced the publication of a study in Nature Communications describing and examining the performance of Genome-to-Treatment (GTRx), an automated, virtual disease management system that integrates a rapid Whole Genome Sequencing (rWGS) diagnosis completed in 13.5 hours with a custom lab information management system and analysis pipeline. Continue Reading….

July 25, 2022 – The earlier the better: New consortium leverages infant screening to accelerate treatment

PharmaVoice | Newborn screening is gaining prominence across the biopharma and healthcare industries amid efforts to detect and treat disease as early as possible. With projections that there could be as many as 60 breakthrough cell and gene therapies approved by the FDA over the next 10 years, the race is on to bring newborn screening practices up to speed. Continue Reading….

June 14, 2022 – Rady Children’s to Evaluate Scalability of Rapid WGS for 400 Known Genetic Diseases

Inside Precision Medicine | Already well known for its groundbreaking effort to rapidly diagnose and treat newborn children with rare, often life-threatening diseases, Rady Children’s Institute for Genomic Medicine (RCIGM) announced it has launched a novel program to evaluate the scalability of new diagnostic and precision medicine that screens for approximately 400 genetic diseases that have available treatment options. Called BeginNGS™ (pronounced “beginnings”), the program has enlisted a Who’s Who of partners in the diagnostic, genetic analysis, and rare disease drug development fields including Alexion, AstraZeneca’s Rare Disease group; Fabric Genomics; Genomemon; Illumina; and TileDB. Continue Reading….

June 6, 2022 – Curation of the Entire Human Genome Requires the Best of Both Human and Artificial Intelligence

Technology Networks | The recent publication of the gapless, telomere-to-telomere human genome assembly serves as a real reminder of the significant work that remained to be completed from initial draft genome to the final sequence assembly. Similarly, while we have learned much about causative genetic variants in human disease over the past many years, there is much work that remains to complete this knowledge and to put it into practice. Continue Reading….

Crains_Detroit_Business_New_Blog_Post_Image_1024x1024

March 10, 2022 – Ann Arbor Software Firm Genomenon Hauls in $20 Million Funding Round

Crain’s Detroit Business | Genomic testing software company Genomenon Inc. has closed on $20 million in a Series B raise led by Farmington Hills-based venture firm Beringea, with money from other in-state and out-of-state investors. The capital raise by the 8-year-old Ann Arbor company, a University of Michigan spin-out, aims to expand Genomenon’s commercial operations. The company’s artificial intelligence-driven data search engine, called Mastermind, serves genetic testing labs, hospitals, pharmaceutical and biopharma companies. Continue Reading….

February 23, 2022 – Genomenon Partners with Don’t Forget Morgan to Provide New Hope for Rare Disease

Healthcare Tech Outlook | Genomenon, Inc., recently announced a partnership with Don’t Forget Morgan, a nonprofit support organization focused on rare disease patients living with Beta-Propeller Protein-Associated Neurodegeneration (BPAN), a progressive disease causing abnormal iron deposits in the brain leading to profound developmental delays The goal of this collaboration is to provide resources to assist researchers and encourage pharmaceutical companies to invest in finding effective treatments for BPAN, as well as empower patient care teams with actionable genetic information. Continue Reading….

February 22, 2022 – Genomenon Partners With Rare-Disease Charity on Variant Identification

GenomeWeb | Genomenon said Tuesday that it has partnered with a charity to identify variants that could help unravel the mystery of a rare pediatric disease. The firm hopes that the collaboration will lead to the development of treatments for beta-propeller protein-associated neurodegeneration, or BPAN, a progressive disease that causes severe developmental delays due to abnormal iron deposits in the brain. Continue Reading….

February 15, 2022 – Genomenon Scores $1.7M SBIR Grant to Curate Genetic Drivers of Disease

BioSpace | Genomenon announced Tuesday that it was awarded a $1.7 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health to help it organize and connect patient DNA to global genomic research in the areas of rare genetic diseases and cancer. The grant is the latest in a steady stream of company advances highlighted by the addition of a chief financial officer in January and several collaborative agreements in the past year. Continue Reading….

February 15, 2022 – The Human Genome Requires Interpretation. AI Can Help Make That Happen

Clinical Lab Manager | The sequencing of the human genome allowed scientists to reliably detect genetic variants in any gene and to understand their role in causing human disease. For clinical practice, though, retrieval and use of this information could only come through a painstaking process of evidence curation highly dependent on results published in the scientific literature. Continue Reading….

January 31, 2022 – Health Tech: Mike Klein On How Genomenon’s Technology Can Make An Important Impact On Our Overall Wellness

Authority Magazine | In recent years, Big Tech has gotten a bad rep. But of course, many tech companies are doing important work making monumental positive changes to society, health, and the environment. To highlight these, Authority Magazine started a new interview series about “Technology Making An Important Positive Social Impact”. In this latest interview, Genomenon’s CEO, Mike Klein, speaks to his experience as a leader in tech, and explains how Genomenon provides the tools and data needed to inform a medical diagnosis from patients’ genetic data. Continue Reading….

January 5, 2022 – Genomenon, OmniTier to Integrate Genome Analysis Technologies

GenomeWeb | Genomenon said Tuesday that it will integrate its Mastermind genomics literature search engine into OmniTier’s CompStor Insight platform, a specialized appliance for tertiary analysis of next-generation sequencing data. The partnership will give CompStor Insight users a list of published articles relevant to their searches and help them quickly find the scientific evidence in Mastermind, the companies said. Continue Reading….

January 5, 2022 – Genomenon and OmniTier Partner to Bring Mastermind’s Evidence Sources to CompStor Insight

Healthcare Tech Outlook | “We are excited to announce a partnership with OmniTier, an organization that is bringing down the cost of genomic analysis for mainstream clinical diagnosis and screening centers.” said Mike Klein, CEO of Genomenon. “With this partnership, OmniTier’s CompStor Insight users will be able to directly link out to relevant Mastermind articles when investigating specific variants of interest.” Continue Reading….

December 1, 2021 – A Rare Moment? Advances Spurring Rare Disease Diagnosis and Treatment

Clinical OMICS | Genomenon’s Mastermind data analytics tool has indexed the full text of millions of scientific articles and prioritizes searches to generate the most relevant results many times faster. “We are on a mission to curate the entire human genome,” says Genomenon CEO Mike Klein. The company has indexed 8.3 million articles so far, and adds about 10,000 articles per week. Its algorithms are AI-informed. Any search can turn up between zero to tens of thousands of hits. “It’s very powerful to find zero hits,” Klein adds. Continue Reading….

November 18, 2021 – Genomenon and Inozyme Pharma Announce Partnership to Advance Genetic Diagnosis for Rare Patients

Healthcare Tech Outlook | Genomenon, Inc., an AI-driven genomics company, announced a partnership with Inozyme Pharma to make critical information readily accessible to genetic testing labs and clinicians. This information will help inform diagnosis and thus treatment decisions in patients with ENPP1 Deficiency, a rare disease also known as generalized arterial calcification of infancy (GACI) or autosomal recessive hypophosphatemic rickets Type 2 (ARHR2). Continue Reading….

November 11, 2021 – Genomenon and Inozyme Pharma Announce Partnership

Clinical Lab Manager | Genomenon, Inc., an AI-driven genomics company, announced a partnership with Inozyme Pharma to make critical information readily accessible to genetic testing labs and clinicians. This information will help inform diagnosis and thus treatment decisions in patients with ENPP1 Deficiency, a rare disease also known as generalized arterial calcification of infancy (GACI) or autosomal recessive hypophosphatemic rickets Type 2 (ARHR2). Continue Reading….

November 11, 2021 – Genomenon, Inozyme Collaborate on MDx Effort for ENPP1 Deficiency

GenomeWeb | Genomenon said Thursday that it has formed a partnership with Inozyme Pharma to deliver molecular diagnostic data on a rare pediatric-onset calcification disorder to testing laboratories and clinicians. The collaboration aims to improve the diagnosis and treatment of ENPP1 deficiency, also known as generalized arterial calcification of infancy or autosomal recessive hypophosphatemic rickets Type 2. Continue Reading….

November 7, 2021 – Giving Drug Researchers Control of Their Data

New technologies such as gene editing and genomics place drug discovery on the front line of a transformation in data management. Genomenon focuses on genomics research, which has experienced explosive growth in data generation. The company uses artificial intelligence to implement a genomics search engine for clinical research and a genomics database called Genomic Landscapes for drug discovery, says CEO Mike Klein. “We ID any variant ever published in association with a disease. We curate those and provide an interpretation with the scientific evidence that goes with it,” Klein says, describing Genomic Landscapes. Continue Reading….

November 5, 2021 – Genomenon, Deep 6 AI Forge Data Partnership for Clinical Trial Matching

GenomeWeb | Genomenon said Thursday that it has entered into a data partnership with Deep 6 AI, a maker of artificial intelligence-based clinical trial acceleration software. Under what the firms dubbed a proof-of-concept agreement, they will effectively explore combining their technology in search of insights about conditions including cancer, Parkinson’s disease, and Wilson’s disease, according to a spokesperson for Ann Arbor, Michigan-based Genomenon. Continue Reading….

October 22, 2021 – Alexion Partners with Genomenon to Deliver Detailed, Curated Variant Data to Speed Diagnosis

Diagnostics World | Most rare diseases have a genetic component, yet most people with rare diseases remain undiagnosed, Thomas Defay, Alexion Pharmaceuticals, told the audience at the Bio-IT World Conference & Expo last month. Thankfully, more and more patients with rare diseases are getting sequenced. At the Bio-IT World conference, Defay focused on the first two goals and highlighted Genomenon’s Mastermind product as the essential tool helping the company better capture existing scientific knowledge and then communicate the most relevant data to healthcare providers. Continue Reading….

September 27, 2021 – A Comprehensive Genomic Landscape for Amyotrophic Lateral Sclerosis (ALS) to Support Precision Medicine Initiatives

The Journal of Precision Medicine | To address the need for a comprehensive view into the literature, Genomenon has used a combination of Artificial Intelligence (AI) and expert curation to produce a Genomic Landscape for ALS – a comprehensive collection of every published variant in 36 ALS-associated genes, interpreted according to the American College of Medical Genetics (ACMG) criteria for assessing variant pathogenicity. The identification and accurate interpretation of any of these variants could conceivably aid in early diagnosis, perhaps even before symptom onset, and subsequent targeted treatment for ALS patients. Continue Reading….

September 26, 2021 – Genomenon Partners With Alexion To Help Genetic Testing Labs Diagnose Rare Diseases

MiTechNews | Genomenon, an AI-driven genomics company, announced it will collaborate with Alexion, AstraZeneca Rare Disease to make critical information needed for the diagnosis and treatment for a set of rare diseases more readily accessible. The goal of this collaboration is to empower genetic testing labs with the data they need to diagnose patients suffering from rare diseases. Continue Reading….

September 20, 2021 – AstraZeneca’s Alexion taps DNA profiler Genomenon for rare disease diagnoses

Fierce Biotech | AstraZeneca’s freshly minted subsidiary Alexion Pharmaceuticals has tapped the artificial intelligence startup Genomenon to help with its work in rare diseases. The collaboration will be aimed at genetic testing laboratories, with the goal of shortening the overall amount of time it takes for a definitive diagnosis, which at times can take several years and as many specialists. Continue Reading….

September 20, 2021 – Genomenon, Alexion Pharmaceuticals Team on Rare Disease Dx

GenomeWeb | Working with Alexion, Ann Arbor, Michigan-based Genomenon will apply its artificial intelligence-driven technology to create what the firm calls a “genomic landscape” for specific conditions, including Wilson disease, complement-mediated thrombotic microangiopathy, lysosomal acid lipase deficiency, and hypophosphatasia. Alexion, which was acquired by AstraZeneca in July, and Genomenon may add other rare diseases to the collaboration in the future. Continue Reading….

August 27, 2021 – Genomenon: More Genomic Data = Higher Diagnostic Rates In 2 International Labs

Michigan Business Network | Genomenon, the AI-driven genomics company, recently announced that it will feature expert clinicians from Acibadem Labgen in Turkey and Héritas in Argentina at this year’s European Society of Human Genetics Virtual Conference. The on-demand talk will highlight the innovative Mastermind Genomic Search Engine, and how it has made a difference in real-life clinical cases. Continue Reading….

August 26, 2021 – Genomenon Hosts Clinical Genomics Experts at European Society of Human Genetics (ESHG) Conference; Acibadem Labgen and Héritas Describe Use of Genomenon’s Mastermind Genomic Search Engine to Solve Real-World Cases

bioquick News | Genomenon, an AI-driven genomics company based in Ann Arbor, Michigan, announced that it will feature expert clinicians from Acibadem Labgen in Turkey and Héritas in Argentina at this year’s European Society of Human Genetics Virtual Conference (August 28-31). The on-demand talk will highlight Genomenon’s innovative Mastermind Genomic Search Engine, and how it has made a difference in real-life clinical cases. Mastermind works by connecting patient genetic data with relevant evidence from scientific literature – essential to the practice of precision medicine for the diagnosis and treatment of cancer and genetic disease. Continue Reading….

August 2, 2021 – New Pharma Report Reveals Novel Genetic Implications For All Diseases

Michigan Business Network | Genomenon has recently published a scientific report on the efficacy of comprehensive Genomic Landscapes for disease and their implications for drug discovery and development within Pharma. The report, entitled Key Findings from the Genomic Landscape for ALS, explores previously unknown insights into pathogenic variants and their functional consequence on disease presentation. Continue Reading….

June 1, 2021 – Genomenon, Nostos Genomics to Integrate Technologies to Improve Rare Disease Dx

GenomeWeb | Genomenon said Tuesday that it has partnered with German bioinformatics startup Nostos Genomics to integrate its Mastermind genomic search engine into the Nostos AIon AI-driven variant interpretation platform. According to Ann Arbor, Michigan-based Genomenon, this integration will allow AIon users to preview lists of published articles related to their searches from within the AIon interface. This, the companies said, will help improve diagnosis of rare genetic diseases. Continue Reading….

May 21, 2021 – New Report Reveals Novel Implications for Neurodegenerative Diseases

Healthcare Tech Outlook | Genomenon, an AI-driven genomics company, announced that it has published a new pharma report: Key Findings from the Genomic Landscape for ALS. Also known as Lou Gehrig’s disease, ALS is a rare neurodegenerative disorder that affects about five in 100,000 individuals and causes devastating motor, cognitive, and behavioral impairment. Furthermore, clinicians and researchers are faced with a frustrating shortage of actionable information, which results in limited genetic testing and few successful drug programs. Continue Reading….

May 6, 2021 – 2021 Luis Villalobos Winners Are Changing the Innovation Landscape

Angel Capital Association | The prestigious Luis Villalobos Award, recognizing the most ingenious and innovative ideas recently financed by members of the Angel Capital Association, was recently awarded to two ACA member-funded companies disrupting their fields. Algenesis, a material science technology company, in the Technology, Services and Consumer category; and Genomenon, a genomic health IT company, in the Life Sciences category. The 2021 Luis Villalobos Award winners are changing the landscape in their respective spaces with ground-breaking innovations. Continue Reading….

March 17, 2021 – Genomenon Completes $5.3M Financing Round

Healthcare Tech Outlook | Genomenon announced that it has completed a $5.3 million financing round in the company. The financing will enable the company to expand its commercial operations, which serve genetic testing labs, pharmaceutical and biopharma companies. Genomenon leverages AI (Artificial Intelligence) to organize the world’s genomic knowledge and put it at the fingertips of doctors and clinicians to diagnose patients suffering from rare & genetic diseases and cancer, and researchers to help create precision medicine targeted at molecular drivers of a disease. Continue Reading….

March 16, 2021 – Genomenon Raises $5.3M in Financing Round

GenomeWeb | Genomenon said on Tuesday that it has raised $5.3 million in a financing round. The Ann Arbor, Michigan-based firm will use the funding to expand its global commercial operations, which serves genetic testing labs, hospitals, pharmaceutical, and biopharma companies. New investors include BroadOak Capital Partners, Green Park & Golf Ventures, Red Cedar Ventures, and Michigan Rise. Current investors, including Invest Detroit Ventures, IrishAngels, Michigan Angel Fund, Invest Michigan, and Atain Specialty Insurance, also participated in the round. Continue Reading….

February 23, 2021 – BC Platforms, Genomenon Team on Analytics for Rare Disease Dx, Research

GenomeWeb | BC Platforms and Genomenon said Tuesday that they have agreed to combine their technologies for rare disease diagnostics and research. The collaboration calls on Genomenon to integrate its Mastermind genomic search engine into two BC Platforms products: the BC|Genome genomic interpretation and analysis platform to support molecular diagnostics and other forms of clinical genomics; and discovery and insight system BC|Insight on the research side. Continue Reading….

January 27, 2021 – Genomenon: SEMINAL STUDY Re: Genomic Variant Interpretation

Michigan Business Network | Yesterday, Genomenon released news that a study conducted by their data scientists at Genomenon has been published in a prestigious peer-reviewed journal focused on advances in genomics. This seminal paper, published in the Computational Genomics section of Frontiers in Genetics, provides insight into how the innovative Mastermind Genomic Search Engine streamlines genomic variant interpretation by leveraging AI and machine learning. This evidence demonstrates how Mastermind manifests a critical paradigm shift within the realm of clinical practice. Continue Reading….

January 26, 2021 – Genomenon Announces Publication of Scientific Paper in Frontiers in Genetics

FirstWord MedTech | Genomenon, Inc., an AI-driven genomics company that connects the world’s genomic knowledge with patient DNA, announced that a seminal paper written by its team of scientists has been published in the Computational Genomics section of Frontiers in Genetics. Frontiers in Genetics is an open-access journal that publishes rigorously peer-reviewed research on genes and genomes relating to all domains of life. Continue Reading….

October 2, 2020 – Clara Health, Genomenon and BrainBaseline Share How They’re Improving the Clinical Trial Process

Pharmaceutical companies need tools to help them more efficiently identify targets, find and enroll patients and monitor and study participants — all tasks that have been made even more challenging by today’s virtual-first world. To help address these challenges, we invited three MATTER startups to share their solutions, and the challenges they solve, to two of our pharmaceutical partners: Eli Lilly and Astellas. Continue Reading….

August 17, 2020 – Thoughts on Advanced Real-World Data and Rare Diseases

Advancements in personalized medicine via innovative data and analytic solutions continue to accelerate opportunities to support rare disease identification, treatment pathways and novel drug development. In the realm of rare and orphan diseases there are many unmet research needs related to therapeutic treatments. Genomenon’s work with Rhythm Pharmaceuticals and how we helped map their clinical development strategy is mentioned in this article from graticule. Continue Reading….

August 11, 2020 – Genomenon’s Klein Named in “Top 25 Biotechnology CEOs of 2020” by TechCEOs

Genomenon announced today that CEO Mike Klein has been named to TechCEOs list of “Top 25 Biotechnology CEOs of 2020”. Klein was recognized for leading Genomenon, one of the most innovative health IT companies in genomics. Genomenon’s AI-powered genomic search engine is used by nearly 10,000 clinicians across 118 countries to diagnose rare disease patients from their DNA. Continue Reading….

May 20, 2020 – Rare Revolution Magazine – CEO Series: Mike Klein of Gemonenon

With a wealth of experience in building and running information technology companies, Mike Klein brought his expertise into the rare disease world and in particular genomic medicine, when he joined Genomenon as CEO. He talks to RARE Revolution about the impact technology is having on diagnosing rare diseases and contributing to drug development, and about the exciting potential that lays ahead. Continue Reading….

December 16, 2019 – BPAN Warriors: A Rare Disease Community’s Search for Connection, Collaboration and a Cure

Platforms such as Genomenon and Mastermind provide patient communities, researchers and industry the ability to rapidly assimilate information. Through the use of increasingly complex and accurate mathematical models and algorithms, large amounts of information, potentially across diseases communities, can now be collected, analyzed and distilled into usable datasets. Continue Reading….

October 15, 2019 – Sophia Genetics, Genomenon Integrate Artificial Intelligence, Genomic Data Software

Genomenon announced today it has partnered with Sophia Genetics to incorporate the Mastermind Genomic Search Engine into the Sophia artificial intelligence platform and Alamut Suite. Under the new partnership, users will be able to apply both technologies to rapidly access genomic evidence linked to human variants, reducing the time needed to interpret a variant and examine its pathogenicity. Continue Reading….

October 10, 2019 – NHS to Benefit as Congenica Adds Two Major Data Sources to Genomic Medicine Platform

Congenica is integrating two powerful sources of data into its genomic medicine platform, which will help clinicians in the NHS using it to diagnose disease. The Wellcome Genome Campus-based digital health technology company is adding data from DECIPHER and Mastermind to its software. Used to support clinical decisions, Congenica’s software accelerates the interpretation of complex genomic data. Continue Reading….

October 4, 2019 – Congenica to Integrate Genomenon’s Mastermind into its Clinical Decision Support Tool

Two new reference data sources, Mastermind and DECIPHER, are being added to Congenica’s clinical decision support platform for genomic data interpretation. Genomenon’s Mastermind, which is used by hundreds of genetic labs worldwide, has indexed nearly 7 million full text articles and 500,000 supplemental data sets and covers over 4.9 million variants found in the medical literature. DECIPHER contains disease-causing variants from over 33,000 rare disease patients. Continue Reading….

October 2, 2019 – Congenica, Genomenon Integrate Clinical Decision Support, Genomic Data Software

Congenica and Genomenon said today that they have partnered to incorporate Genomenon’s Mastermind Genomic Search Engine results into Congenica’s clinical decision support platform. Congenica, based in Cambridge, UK, markets software that enables the analysis and interpretation of genomic data to help healthcare professionals make more rapid and accurate diagnoses. Continue Reading….

August 20, 2019 – Genomenon Enters Chinese Market With Shanghai Shanyi Partnership

Ann Arbor, Michigan-based Genomenon said today that the new partnership will allow the company to bring its Mastermind genomic search engine to clinical laboratories in China. “Our partnership with Shanghai Shanyi will allow us to expand our footprint in the China market, seamlessly integrating with their other best-of-breed end-to-end clinical [next-generation sequencing] solutions,” Genomenon CEO Mike Klein said in a statement. Continue Reading….

August 19, 2019 – Finding the Needle in the Haystack of Rare Disease

Through the use of Genomenon’s AI-driven Mastermind Genomic Search Engine, the Rare Genomics Institute succeeded where a leading genetics laboratory had failed in securing diagnosis for an ultra-rare disease patient. Romina Ortiz, Chief Operating Officer and Vice President, Patient Advocacy at the Institute explains how the platform could prove transformative in tackling the challenges of ultra-rare disease diagnosis. Continue Reading….

August 6, 2019 – Genomenon Wins SBIR Grant to Develop ‘Micropublications’ for Variant Interpretation

Genomenon said today it has won a Small Business Innovation Research (SBIR) grant from the NIH’s National Human Genome Research Institute (NHGRI). Funding from the grant, valued at $152,946, will go toward creating a platform for producing and sharing “micropublications” across the genomics research community, as well as continuing Genomenon’s efforts to automate variant interpretation based on data from published studies. Continue Reading….

July 10, 2019 – Genomenon Provides Quick Answers on Fusion Genes

Well over 20,000 fusion genes have been documented since the first one was discovered in 1973…says Mark Kiel, MD, PhD, founder and chief science officer of Genomenon. Mastermind organized all the evidence (roughly 30,000 articles) on the 507 “bad actor” genes comprising the Illumina TruSight Fusion Gene Panel. It then compiled a list of the well-known fusion partners—numbering between one and 95—involved in 2,500 fusion events in those genes in a new report… Continue Reading….

May 22, 2019 – Ann Arbor Company is an “Engine” for Growth with Tips to Share on SBIR Success

Genomenon, a leading genomic research company, was honored with a Best of Show award at the Bio-IT World Conference & Expo in Boston. The prestigious award recognizes the best in innovative life sciences industry product solutions, in this case Genomenon’s Mastermind Genomic Search Engine. A panel of experts from academia, industry, pharma and biotech, bases their judgement on uniqueness, importance to the industry, and the ability to offer a compelling return on investment. Continue Reading….

May 14, 2019 – KGI is the First Participant in Genomenon Genetics Education Program

Keck Graduate Institute (KGI) has become the first academic partner in a new genomics education program launched by Genomenon, creator of the Mastermind genomic search engine providing search results from the full-text database of 6.5 million genomic-focused scientific articles. “We feel strongly that Mastermind is the best way to interpret variants and make clinical decisions more quickly. We realized that schools like KGI are the future of genomics. We’re partners in equipping the next generation of genomic scientists,” says Candace Chapman, director of marketing for Genomenon, a privately held company founded in Ann Arbor, Michigan, in 2014.” Continue Reading….

May 14, 2019 – KGI First Academic Partner for Genomenon’s Genomics Educators Program

Genomenon announced today the launch of its Genomics Educator Program and named the Keck Graduate Institute(KGI) as its first academic partner for this effort which provides graduate level students with access to its flagship product the Mastermind Genomic Search Engine. According to Candace Chapman, director of marketing for Genomenon, the relationship with KGI was built off a conversation struck up between Fortini and Genomenon executives in 2017 at the American Society of Human Genetics (ASHG)Annual Conference. “Barbara has shared great feedback as a Mastermind user since then, and she was the first person we reached out to for the Genomic Educator’s Program,” Chapman told Clinical OMICs in an exclusive interview. “It’s safe to say that Barbara and the Keck program was a major inspiration.” Continue Reading….

May 9, 2019 – Rare Genomics Institute Brings Hope to Rare Disease Patients

“Sometimes there is only one research paper that can connect a patient’s DNA with a diagnosis. Searching through millions of research papers to find a patient’s genetic mutation can be like trying to find a needle in a haystack. With advanced AI techniques used by Genomenon, the needle can pop right into view.” said Dr. Ray. “I can say with certainty that without the findings obtained from Genomenon, I would not have been able to provide a diagnosis for this patient.” Continue Reading….

May 7, 2019 – Michigan 50 Companies to Watch – Genomenon

Jeffrey Mosher talks with Mike Klein, CEO of one of Michigan 50 Companies to Watch in 2019, Genomenon, Ann Arbor, MI. Mike Klein with over 25 years of developing, building and growing 4 different high tech companies. In fact Genomenon is the third company Mike has led to being honored by the Michigan 50 Companies to Watch category! Genomenon has replaced the manual search process in gene and variant interpretation with a genomic search engine and database of all the disease-gene-variant relationships found in the full text of the scientific literature. Our technology is revolutionizing the way genetic diagnoses and discoveries are made by making it easier to get rapid insight into prioritized, clinically relevant literature for both clinical decision making and research projects. Continue Reading….

April 18, 2019 – BioIT World Conference Highlights: Altos and WASAI, Genomenon and Google, 1 CellBio and More

The BioIT World Conference & Expo is going on in Boston, Massachusetts, highlighting companies and breakthroughs working on the data end of life sciences, whether that’s blockchain, artificial intelligence, machine learning, data science, deep learning or others. Here’s a sample of some of the stories out of the conference. Genomenon Partners with Google for Genomic Data Continue Reading….

April 17, 2019 – BIO-IT World Announces 2019 Best of Show Award Winners

Today BIO-IT World announced the 2019 winners of the Best of Show Awards Program to a packed audience at the BIO-IT World Conference & Expo. The awards program recognizes the best of the life sciences industry on display at the BIO-IT World Conference & Expo in Boston. “The innovation on display by BIO-IT World exhibitors never disappoints,” said BIO-IT World Editor Allison Proffitt. “It’s always a treat to see the work and dedication from companies firsthand, and we are excited to shine a spotlight on the best life sciences has to offer.” Continue Reading….

April 8, 2019 – Revolutionizing Genomics, How a Tech Company is Empowering Personalized Medicine by Directing Information Straight to Doctors’ Fingertips

Genomenon is a DNA interpretation software company that was born out of the growing gap between big data and diagnostic decision-making. The field of genomics and DNA sequencing was unimaginable 25 years ago. The real challenge now is making that information practical, and that’s the niche in which… Genomenon fits. Continue Reading….

April 1, 2019 – The Rise of Genetic Testing Companies and DNA Data Race

It is said that this is the best of times for direct to consumer (DTC) genetic testing companies, human disease genomics, and the launch of genomic data marketplaces. Due to advances in technology and the availability of cost-effective consumer genotyping kits, massive genomic data sets from human patients and controls are being created from across nations. As a result, it is not only the continued growth in the number of disease genes identified, but it will also advance a deepening of our understanding of the fundamental human genetic architecture and disease states. Moreover, we will also see the commercialization of genomic data. Continue Reading….

March 15, 2019 – Mastermind Scientists Help Diagnose Rare Diseases

The Rare Genomics Institute, a nonprofit organization providing support to undiagnosed rare disease patients, announced on Rare Disease Day 2019 that they had used the Mastermind Genomic Search Engine, a clinical decision support tool by Genomenon, to diagnose a rare disease patient. We spoke to Mark Kiel, MD, PhD, Founder and Chief Science Officer at Genomenon and Romina Ortiz, COO at the Rare Genomics Institute, to learn more about the application of this technology in rare diseases. Continue Reading….

February 28, 2019 – Rare Genomics Institute Uses Genomenon’s Mastermind to Diagnose Patient

Rare Genomics Institute said today it successfully diagnosed a previously undiagnosed patient using Genomenon’s Mastermind Genomic Search Engine.The announcement, timed to coincide with Rare Disease Day 2019, comes four months after the partners launched a collaboration in which Genomenon agreed to donate licenses allowing clinical scientists working with Rare Genomics Institute to access Mastermind. Continue Reading….

February 23, 2019 – AI-Based Software Provider and Genomic Search Company Partner to Improve Rare Disease Diagnostics

Diploid, an artificial intelligence (AI)-based software provider for rare disease diagnostics, and Genomenon, a genomic search company, are partnering to improve genome interpretation for rare disease diagnostics. Genomenon’s Mastermind Genomic Search Engine filters and prioritizes millions of articles about genomics to find the most useful and meaningful citations. The search engine saves scientists hours of literature curation per case, and improves the chances of finding key genetic information that could be critical for a patient’s diagnosis. Continue Reading….

February 6, 2019 – David Anstey Joins Genomenon As Vice President Sales, Business Development

ANN ARBOR – Genomic search company Genomenon has hired industry veteran David Anstey as Vice President of Sales. In his new role at Genomenon, Anstey is responsible for building out and leading the company’s sales and business development efforts. “Dave brings 20 years of experience selling into life science companies, and he has an excellent track record of driving growth and building partnerships with his customers” said Mike Klein, CEO of Genomenon. “We’re excited to have Dave join our team and help drive our success.” Continue Reading….

July 31, 2018 – Genomenon Wins Phase 2 Small Business Innovation Research Grant

Genomic Data Search company Genomenon has been awarded a Phase 2 Small Business Innovation Research grant by the National Institutes of Health. The grant will be used to develop and apply machine learning and artificial intelligence algorithms to variant interpretation, the single biggest hurdle in scaling the adoption of genomic sequencing in both clinical and precision medicine applications. Continue Reading….

MASTERMIND GENOMIC SEARCH ENGINE
Accelerate Discovery. Search Faster.

Learn More